Larry is the US Commercial Lead for SHP621. SHP621 is being developed as a treatment for Eosinophilic Esophagitis

Larry has over 17 years of experience in pharmaceutical/vaccine sales and marketing and has developed a reputation for being an effective leader, strategist, and planner.  He possesses a deep understanding of the pediatric vaccines market, having worked across multiple brands including Gardasil, MMRII, as well as the launches of Proquad, RotaTeq and MenHibrix.  Larry has also gained experience in pharmaceutical marketing as Marketing Director for the blockbuster cardiovascular products Zetia and Vytorin.   In addition to his experience as a product marketer, Larry has held positions in Sales, Marketing Communications, and Market Research.  In his prior role at GSK, Larry was the Senior Director of the Pediatric Vaccine Commercial Strategy Team and was responsible for delivering gross revenue greater than $1B.